ImmunityBio
IBRX
62 hedge funds and large institutions have $124M invested in ImmunityBio in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 32 increasing their positions, 10 reducing their positions, and 8 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 10
60% more call options, than puts
Call options by funds: $599K | Put options by funds: $374K
0% more funds holding
Funds holding: 62 → 62 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
28% less capital invested
Capital invested by funds: $172M → $124M (-$48.4M)
Top Buyers
Top Sellers
IBRX Hedge Fund Activity: Q2 2016 in Review
62 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2016, worth a combined $124M — down 28% from $172M a quarter earlier.
Fund positioning in IBRX was balanced in Q2 2016: 8 funds opened new positions, 8 closed out, 32 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $1.76M. The largest seller was RS Investment Management, exiting entirely with an estimated $9.15M sold.
- 62 institutional investors held ImmunityBio (IBRX) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $124M of ImmunityBio stock for Q2 2016, down 28% quarter-over-quarter.
- 8 funds opened new ImmunityBio positions in Q2 2016 and 8 closed out, a net change of 0 holders.
- The largest ImmunityBio buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $1.76M added.
- The largest ImmunityBio seller in Q2 2016 was RS Investment Management, an estimated $9.15M sold.
Based on aggregated 13F filings for Q2 2016.